• Users Online: 158
  • Print this page
  • Email this page
PROFESSIONAL RESOURCE
Year : 2018  |  Volume : 1  |  Issue : 2  |  Page : 139-162

Immunotherapy protocols in lung cancer


Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Sharada Mailankody
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai - 400 012, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/CRST.CRST_18_18

Get Permissions

Immunotherapy has emerged as a valuable treatment option in many advanced malignancies (especially lung cancer). The PD-1 inhibitors (nivolumab and pembrolizumab) and the PD-L1 inhibitors (durvalumab and atezolizumab) have been approved for use in various cancers, alone or in combination with chemotherapy. The protocols for the PD-1/PD-L 1 blockers are listed below. The various indications for these PD-1/PD-L1 blockers, baseline evaluation, monitoring during therapy, and guidelines for the management of immune-related adverse events are described below.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed60    
    Printed9    
    Emailed1    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal